Surface Oncology to Present at the Baird Global Healthcare Conference
September 09 2020 - 1:15PM
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology
company developing next-generation immunotherapies that target the
tumor microenvironment, today announced that Jeff Goater, its chief
executive officer, and Robert Ross, M.D., its chief medical
officer, will present at the upcoming Robert W. Baird Global
Healthcare Conference, discussing Surface Oncology's lead programs,
SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as
Surface’s emerging pre-clinical pipeline, highlighted by SRF813
(targeting CD112R, aka PVRIG).
The presentation will be in the format of a fireside chat and
take place virtually on Thursday September 10, 2020 at 1:25 pm
EDT.
About Surface Oncology:
Surface Oncology is an immuno-oncology company developing
next-generation antibody therapies focused on the tumor
microenvironment. Its pipeline includes two wholly-owned lead
programs targeting CD39 (SRF617) and IL-27 (SRF388), a
clinical-stage collaboration with Novartis targeting CD73 (NZV930),
and two preclinical programs, each focused primarily on activating
natural killer cells (via targeting CD112R, also known as PVRIG
(SRF813)) or depleting regulatory T cells (via targeting CCR8
(SRF114)). Surface’s novel cancer immunotherapies are designed to
achieve a clinically meaningful and sustained anti-tumor response
and may be used alone or in combination with other therapies. For
more information, please visit www.surfaceoncology.com.
Contacts:InvestorsMatt
Lanematt@gilmartinir.com617-901-7698
Media Tom Donovan
tom@tenbridgecommunications.com857-559-3397
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Surface Oncology (NASDAQ:SURF)
Historical Stock Chart
From Apr 2023 to Apr 2024